These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 11366890)

  • 21. IL-2 for HIV: the long march toward FDA approval. Food and Drug Administration.
    Sterritt C
    GMHC Treat Issues; 1997 Sep; 11(9):1-3. PubMed ID: 11364749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA notifications. Tenofovir in India receives tentative approval.
    AIDS Alert; 2009 Jun; 24(6):70-1. PubMed ID: 19544609
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA approves Viread for HIV-1 infection.
    FDA Consum; 2002; 36(1):5. PubMed ID: 11881601
    [No Abstract]   [Full Text] [Related]  

  • 24. Viread gets FDA nod.
    Rodriquez E
    Posit Living; 2001 Dec-2002 Jan; 10(7):33. PubMed ID: 11808509
    [No Abstract]   [Full Text] [Related]  

  • 25. More trouble for adefovir.
    Gilden D
    GMHC Treat Issues; 1999 Apr; 13(4):3. PubMed ID: 11366975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tenofovir for the treatment of hepatitis B virus.
    Jenh AM; Thio CL; Pham PA
    Pharmacotherapy; 2009 Oct; 29(10):1212-27. PubMed ID: 19792994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir: FDA hearing October 3, public comment deadlines September 26.
    James JS
    AIDS Treat News; 2001 Aug; (370):3-4. PubMed ID: 11570163
    [No Abstract]   [Full Text] [Related]  

  • 28. Tenofovir DF expanded access. Criteria for U.S. program.
    AIDS Treat News; 2001 Feb; (360):2-3. PubMed ID: 12173565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tenofovir approved: broad indication.
    James JS
    AIDS Treat News; 2001 Oct; (373):2-3. PubMed ID: 11768879
    [No Abstract]   [Full Text] [Related]  

  • 31. Ten years of HAART.
    Harrington M
    Res Initiat Treat Action; 2005; 11(1):28-38. PubMed ID: 16208817
    [No Abstract]   [Full Text] [Related]  

  • 32. HAART at 10--a CFA timeline.
    Res Initiat Treat Action; 2005; 11(1):6-27. PubMed ID: 16208816
    [No Abstract]   [Full Text] [Related]  

  • 33. [Once daily administration improves therapy adherence in HAART. New substance class with more powerful reserves against virus resistance].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():86-9. PubMed ID: 11373792
    [No Abstract]   [Full Text] [Related]  

  • 34. Expanded access.
    Proj Inf Perspect; 1999 Sep; (28):8. PubMed ID: 11367366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adefovir dipivoxil reduces HBV DNA.
    Newsline People AIDS Coalit N Y; 1999 Jan; ():36. PubMed ID: 11367193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
    Côté HC; Magil AB; Harris M; Scarth BJ; Gadawski I; Wang N; Yu E; Yip B; Zalunardo N; Werb R; Hogg R; Harrigan PR; Montaner JS
    Antivir Ther; 2006; 11(1):79-86. PubMed ID: 16518963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combinations of nucleoside/nucleotide analogues for HIV therapy.
    Barreiro P; García-Benayas T; Rendón A; Rodríguez-Novoa S; Soriano V
    AIDS Rev; 2004; 6(4):234-43. PubMed ID: 15700622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generic Truvada approved.
    AIDS Patient Care STDS; 2009 May; 23(5):395. PubMed ID: 19422066
    [No Abstract]   [Full Text] [Related]  

  • 40. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.